Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pseudomonas syringae is a widespread Gram-negative bacterium and a major plant pathogen that affects a broad spectrum of agricultural crops and wild plants (Hirano & Upper, 2000). It is characterized by its ability to exist as an epiphyte on leaf surfaces before entering plant tissues through stomata or wounds to cause diseases such as bacterial speck, canker, and blight (Mansfield et al., 2012). A defining feature of many P. syringae strains is the production of ice nucleation proteins, which promote ice crystal formation at relatively high temperatures, leading to frost damage that facilitates bacterial entry (Lindow, 1987). The bacterium employs a type III secretion system to deliver effector proteins into host cells, suppressing plant immunity and promoting nutrient release (Alfano & Collmer, 2004). While it is a critical target in agricultural biotechnology and crop protection, it is not a human therapeutic target or a specific molecular receptor. Management of P. syringae infections primarily relies on copper-based bactericides and specific antibiotics like streptomycin, although the rapid evolution of resistance remains a significant concern for global food security (Sundin & Wang, 2018).
Antibiotics like streptomycin and oxytetracycline inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit (Sundin & Wang, 2018). Copper-based bactericides act by releasing Cu2+ ions that denature proteins and disrupt cell membranes through oxidative stress (Lamichhane et al., 2018).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudomonas syringae (P. syringae).